VanEck Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$414M Sell
344,960
-94,052
-21% -$96.1M 0.25% 56
2026
Q1
$404M Buy
439,012
+5,265
+1% +$5.34M 0.3% 60
2025
Q4
$466M Buy
433,747
+121,698
+39% +$116M 0.39% 49
2025
Q3
$238M Buy
312,049
+6,260
+2% +$4.66M 0.22% 97
2025
Q2
$238M Buy
305,789
+35,910
+13% +$27.9M 0.27% 82
2025
Q1
$223M Sell
269,879
-3,660
-1% -$3.05M 0.29% 88
2024
Q4
$211M Buy
273,539
+4,070
+2% +$3.37M 0.27% 91
2024
Q3
$243M Buy
269,469
+28,465
+12% +$25.6M 0.3% 77
2024
Q2
$218M Sell
241,004
-4,283
-2% -$3.43M 0.31% 75
2024
Q1
$191M Buy
245,287
+23,286
+10% +$16.6M 0.29% 96
2023
Q4
$129M Buy
222,001
+12,447
+6% +$7.27M 0.24% 97
2023
Q3
$113M Buy
209,554
+23,950
+13% +$12.3M 0.25% 105
2023
Q2
$87M Sell
185,604
-218
-0.1% -$91.4K 0.19% 116
2023
Q1
$63.8M Sell
185,822
-25,360
-12% -$8.55M 0.15% 131
2022
Q4
$77.3M Sell
211,182
-6,091
-3% -$2.16M 0.2% 123
2022
Q3
$70.3M Buy
217,273
+5,781
+3% +$1.83M 0.21% 119
2022
Q2
$68.6M Buy
211,492
+42,793
+25% +$12.8M 0.18% 129
2022
Q1
$48.3M Buy
168,699
+1,871
+1% +$482K 0.1% 179
2021
Q4
$46.1M Buy
166,828
+18,958
+13% +$4.81M 0.11% 172
2021
Q3
$34.2M Buy
147,870
+16,456
+13% +$4.06M 0.09% 197
2021
Q2
$30.2M Buy
131,414
+60,930
+86% +$12.2M 0.07% 215
2021
Q1
$13.2M Sell
70,484
-23,116
-25% -$4.52M 0.04% 300
2020
Q4
$15.8M Buy
93,600
+4,266
+5% +$637K 0.05% 233
2020
Q3
$13.2M Sell
89,334
-13,891
-13% -$2.15M 0.04% 224
2020
Q2
$16.9M Sell
103,225
-43,942
-30% -$6.75M 0.06% 197
2020
Q1
$20.4M Sell
147,167
-17,809
-11% -$2.45M 0.1% 142
2019
Q4
$21.7M Buy
164,976
+54,817
+50% +$6.35M 0.08% 163
2019
Q3
$12.3M Sell
110,159
-5,728
-5% -$638K 0.06% 201
2019
Q2
$12.8M Buy
115,887
+4,494
+4% +$529K 0.06% 204
2019
Q1
$14.5M Sell
111,393
-60,224
-35% -$7.32M 0.07% 189
2018
Q4
$19.9M Sell
171,617
-222,536
-56% -$24.9M 0.1% 165
2018
Q3
$42.3M Sell
394,153
-243,556
-38% -$24.3M 0.21% 113
2018
Q2
$54.4M Buy
637,709
+50,207
+9% +$4.12M 0.25% 93
2018
Q1
$45.5M Buy
587,502
+57,487
+11% +$4.63M 0.23% 98
2017
Q4
$44.8M Sell
530,015
-16,953
-3% -$1.44M 0.22% 104
2017
Q3
$46.8M Buy
546,968
+21,939
+4% +$1.8M 0.24% 87
2017
Q2
$43.2M Buy
525,029
+5,190
+1% +$423K 0.24% 88
2017
Q1
$43.7M Buy
519,839
+41,442
+9% +$3.32M 0.19% 99
2016
Q4
$35.2M Buy
478,397
+81,829
+21% +$6.09M 0.18% 99
2016
Q3
$31.8M Sell
396,568
-10,092
-2% -$808K 0.15% 98
2016
Q2
$32M Buy
406,660
+241,134
+146% +$18.2M 0.16% 90
2016
Q1
$11.9M Sell
165,526
-34,816
-17% -$2.63M 0.08% 160
2015
Q4
$16.9M Buy
200,342
+11,473
+6% +$952K 0.13% 148
2015
Q3
$15.8M Sell
188,869
-24,531
-11% -$2.07M 0.12% 142
2015
Q2
$17.8M Sell
213,400
-4,327
-2% -$330K 0.11% 159
2015
Q1
$15.8M Buy
217,727
+8,832
+4% +$629K 0.09% 170
2014
Q4
$14.4M Sell
208,895
-60,963
-23% -$4.11M 0.09% 173
2014
Q3
$17.5M Buy
269,858
+15,017
+6% +$951K 0.09% 159
2014
Q2
$15.8M Buy
254,841
+15,019
+6% +$896K 0.07% 161
2014
Q1
$14.1M Sell
239,822
-506,485
-68% -$28.3M 0.07% 166
2013
Q4
$38.1M Buy
746,307
+541,846
+265% +$27.1M 0.19% 97
2013
Q3
$10.3M Sell
204,461
-4,736
-2% -$248K 0.05% 173
2013
Q2
$10.3M Buy
+209,197
New +$11.4M 0.06% 167

Other funds holding LLY

VanEck Associates's LLY Position: Q2 2026 in Review

VanEck Associates reduced its Eli Lilly (LLY) stake by 21% in Q2 2026, selling an estimated $96.1M and leaving 344,960 shares worth $414M. The position accounts for 0.25% of the portfolio, ranked #56.

VanEck Associates first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. The position peaked at $466M in Q4 2025. 4,593 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • VanEck Associates held 344,960 shares of Eli Lilly worth $414M as of Q2 2026.
  • VanEck Associates sold 94,052 Eli Lilly shares in Q2 2026, an estimated $96.1M.
  • Eli Lilly made up 0.25% of VanEck Associates's portfolio in Q2 2026, its #56 holding.
  • VanEck Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
  • VanEck Associates's Eli Lilly position peaked at $466M in Q4 2025.
  • 4,593 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.